Related Experiment Video
Updated: Jan 15, 2026
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
Zanubrutinib as a salvage therapy for ibrutinib-resistant chronic lymphocytic leukemia: a case report
Zhenhui Lv1, Ping Lu1, Changhua Jing1
1Department of Hematology, Zibo Central Hospital, Zibo, Shandong, China.
Objectives:
This case report aims to evaluate the efficacy of zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor (BTKi), in achieving durable disease control for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have experienced disease progression on ibrutinib, a first-generation BTKi.
Methods:
A patient with CLL/SLL who developed resistance to ibrutinib was treated with zanubrutinib. The patient's clinical response, including disease progression, symptom control, and adverse effects, was monitored over time.
Results:
The patient demonstrated significant and durable disease control following the initiation of zanubrutinib therapy. The treatment was well-tolerated, with no severe adverse effects reported, suggesting that zanubrutinib may be an effective therapeutic option for ibrutinib-resistant CLL/SLL patients.
Discussion:
The findings from this case report suggest that zanubrutinib may provide a viable treatment option for patients with CLL/SLL who have progressed on ibrutinib. Further studies and clinical trials are warranted to confirm these observations and to explore the broader applicability of zanubrutinib in managing ibrutinib-resistant CLL/SLL.
